LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2025
0mins
Source: PRnewswire
Nasdaq Delisting Notification: LakeShore Biopharma received a letter from Nasdaq indicating non-compliance with the Bid Price Rule due to its share price being below $1.00 for 30 consecutive business days, and it is ineligible for the standard compliance period due to a recent reverse stock split.
Appeal Options: The company has until September 18, 2025, to request a hearing to appeal the delisting decision, which would temporarily stay the suspension of its securities pending the outcome of the appeal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
